Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 530057 | NSE Symbol : | ISIN : INE984E01035 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
06-May-2025	12-May-2025	Quarterly Results	Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2025 inter alia to consider and approve The Audited Standalone and Consolidated Financial statements and Financial results of the Company for the quarter and year ended March 31 2025 and 2. Any other business with the permission of Chair. Audited Standalone and Consolidated Financial Results along with Audit Report of the Company for the Quarter and Financial Year ended 31st March, 2025. The Board of Directors of the Company at its meeting held today i.e. Monday, 12th May, 2025 at Registered Office of the Company has inter alia considered and approved the following businesses: 1.Audited Standalone and Consolidated Financial Results along with Audit Report of the Company for the Quarter and Financial Year ended 31stMarch, 2025 . 2. Appointment of M/s. Rahul Doshi & Co., Chartered Accountants (FRN: 150982W, Membership No. 117160) as Internal Auditor of the Company for the Financial year 2025-26. 3. Appointment of Mr. Chintan K. Patel, Practicing Company Secretary (Membership No. A31987, COP: 11959) as Secretarial Auditor of the Company for the Financial year 2024-25.4. Appointment of Mr. Hitesh Pradeep Rijwani (DIN: 11030634) as an Additional Director (Non- Executive, Independent Director) and 5. Reconstitution of Committees of the Board w.e.f. 12thMay, 2025. (As Per BSE Announcement Dated on: 12/05/2025) Revised Outcome of the Board Meeting pertaining to clarification on Typographical Error in the Notes related to Financial Results submission for the quarter and year ended March 31, 2025 (As Per BSE Announcement Dated on 13.05.2025)
20-Mar-2025	20-Mar-2025	Change in Other Executives	Appointment of Ms. Siddhi Shah as Company Secretary w.e.f. 20.03.2025
24-Jan-2025	31-Jan-2025	Quarterly Results	Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 inter alia to consider and approve 1. Unaudited Standalone and Consolidated Results along with Limited Review Report for the Quarter and Nine Months ended 31st December 2024; 2. Any other business with the permission of Chairman. Outcome of the Board Meeting held on 31st January, 2025 at 04:00 P.M. inter alia considered and approved Un-audited Financial Results for the Quarter and Nine Months Ended 31st December, 2024. (As Per BSE Announcement Dated on: 31/01/2025)
10-Oct-2024	17-Oct-2024	Quarterly Results	Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/10/2024 inter alia to consider and approve Notice is hereby given that meeting of Board of Directors scheduled to be held on Thursday 17th October 2024 at 5:00 PM at Registered Office of the Company. Pursuant to provisions of Regulation 33 of SEBI (LODR) Regulations, 2015, Board of DIrectors has approved Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2024. (As Per BSE Announcement dated on 17.10.2024)
02-Aug-2024	08-Aug-2024	Quarterly Results	Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve UNAUDITED RESULTS FOR QUARTER ENDED 30TH JUNE 2024 unaudited results for the Quarter ended 30th June, 2024 along with Limited Review Report. (As Per BSE Announcement dated on 08.08.2024)
29-Jun-2024	05-Jul-2024	AGM	Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/07/2024 inter alia to consider and approve 1) To consider and approve the Directors Report and Secretarial Audit Report along with annexure for the F.Y. 2023-24; 2) To approve appointment of M/s. Rahul Doshi & Co Chartered Accountants as Internal Auditor of the Company for the Financial Year 2024-25; 3) To approve appointment of Mr. Chintan K. Patel Practicing Company Secretary as a Secretarial Auditor of the Company for F.Y. 2023-24; 4) To take noting of Resignation of Girish Bhatt as Non-Executive Director; 5) To revise and increase the limit of Borrowing power pursuant to Section 180 (1) (c ) of the Companies Act 2013; 6) To Convene the 42nd AGM of the Members of the Company and approve the draft notice of 42nd Annual General Meeting (AGM) of the Company; 7) To consider and fix the Book Closure date for the purpose of 42nd AGM of the Company; 8) To appoint Mr. Chintan K. Patel Practicing Company Secretary (Mem No: A31987 COP: 11959) as Scrutinizer to ascertain voting process of 42nd AGM; Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Friday, 5th day of July, 2024 has discussed agendas as described in Outcome. (As per BSE Announcement Dated on 05/07/2024)
19-Apr-2024	30-Apr-2024	Quarterly Results	Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/04/2024 inter alia to consider and approve (i) Audited results for the quarter and year ended on March 31st 2024. (ii) Appointment of Independent Director Results for Quarter & financial year ended on 31st March, 2024 Board Meeting held today for consideration and taken on record the following; 1. Audited standalone and consolidated financial results for quarter and year ended 31.03.2024 2. Resignation of Ms. Apeksha Vyas as Independent Director 3.Appointment of Ms. Rina Kumari as Independent Director 4.Resignation of Mr. Sunil Shah as Independent Director 5. Appointment of Mr. Aagam Shah as Independent Director (As per BSE Announcement Dated on 30/04/2024)
30-Jan-2024	06-Feb-2024	Quarterly Results	Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2024 inter alia to consider and approve UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED DECEMBER31ST 2023 OUTCOME OF THE BOARD MEETING FOR UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHD ENDED 31ST DECEMBER,2023 (As Per BSE Announcement Dated on: 06/02/2024)
11-Oct-2023	26-Oct-2023	Quarterly Results	Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2023 inter alia to consider and approve The Un-audited financial results for quarter ended 30th September 2023. Any other business with the permission of Chair In continuation of our letter Dated October 11, 2023 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, October 26, 2023 at Registered Office of the Company has inter alia considered and approved the Un-audited Financial Results along with Limited Review Report of the Company for the Quarter and Half- Year ended on 30th September, 2023; The Board of Directors of the Company at it''s meeting held today i.e. 26th October, 2023 at Registered office of the Company has inter alia considered & approved the Un-audited Financial Results along with Limited Review Report of the Company for the Quarter & Half year ended on 30th September, 2023. (As Per BSE Announcement Dated on 26.10.2023)
03-Aug-2023	10-Aug-2023	Quarterly Results	Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 inter alia to consider and approve Un-audited Standalone and Consolidated Financial Results for the Quarter Ended 30th June 2023. Board at its meeting held today i.e.: 10.08.2023 has upon review by audit committee has considered and approved the unaudited standalone and consolidate financial results for the quarter ended June 30, 2023. (As Per BSE Announcement dated on 10.08.2023) Revised Outcome of the Board Meeting for Quarter ended June 30, 2023. (As Per BSE Announcement Dated on 01/09/2023)
26-Jun-2023	30-Jun-2023	Change in Auditors	Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/06/2023 inter alia to consider and approve 1) To consider and approve the Directors Report and Secretarial Audit Report along with annexure for the Financial Year 2022-23. 2) Appointment of Chintan K. Patel Company Secretary as a Secretarial Auditor of the Company for the financial year 2023-24. 3) To propose regularization of appointment of Ms. Apeksha Vyas (DIN: 09469295) as Non-Executive Independent Director of the Company in the ensuing Annual General Meeting. 4) To approve the draft notice of 41st Annual General Meeting (AGM). 5) To consider and fix the Book Closure date for the purpose of 41st Annual General Meeting (AGM). 6) To appoint scrutinizer to ascertain voting process of 41st Annual General Meeting (AGM). 7) Increase in borrowing limits to Rs. 200000000/- (Rupees Twenty Crore) or the aggregate of the paid up capital and free reserves of the Company whichever is higher. 8) Any other business as Board deem fit to discuss with the permission of the Chair 1. Considered and approved the Director's report and secretarial Audit Report for the Financial Year ended 31st March, 2023. 2. Approved Appointment of Mr. Chintan K. Patel, as a Secretarial Auditor of the Company for the Financial Year 2023-24. 3. Approved the proposal regarding regularization of Ms. Apeksha Vyas as Non-Executive Independent Director of the Company in the ensuing AGM 4. Approved the draft notice of 41st AGM, which is scheduled to be held on Monday, 24th July, 2023 at 03:00 P.M. 5. Book Closure date for the purpose of 41st AGM is fixed from 18th July, 2023 to 24th July, 2023. 6. Approved the Appointment of Mr. Chintan Patel, as a Scrutinizer to ascertain Voting Process of 41st AGM. 7. Approved the borrowing to be increased to Rs. 20,00,00,000/- subject to approval of members in the ensuing AGM. 8. Approved the proposal regarding regularization of Mr. Jayendra Mehta as Managing Director of the Company in the ensuing AGM. (As Per BSE Announcement dated on 30.06.2023) Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('listing obligations') read with Schedule III to the Listing Regulations, this is to inform you that the Board of Directors of the Company, at it''s Meeting held today, i.e. on Friday, June 30, 2023 at Registered office of the Company has inter alia considered that the Book closure date for the Purpose of 41st Annual General Meeting (AGM) is fixed from 18th July, 2023 to 24th July, 2023. Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 ('listing Regulations') read with Schedule III to the Listing Regulations, this is to inform you that the Board of Directors of the Company, at its Meeting held on Friday, June 30, 2023 at registered Office of the Company, inter alia has considered and approved the notice of 41st AGM which is scheduled to be held on Monday, July 24th, 2023 at 3:00 P.M. (As Per BSE Announcement Dated on 01.07.2023)
28-Mar-2023	25-Apr-2023	Accounts	Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/04/2023 inter alia to consider and approve 1. Audited standalone and consolidated financial statements and financial results of the Company for the quarter and year ended March 31 2023; 2. Appointment of Independent Director on the Board of the Company; 3. Appointment of Managing Director of the Company; Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations''), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday, April 25, 2023 at Registered Office of the Company has inter alia considered and approved the followings: 1. Audited Standalone and Consolidated Financial Results along with Audit Report of the Company for the Quarter and Financial Year ended on 31st March, 2023 which is enclosed herewith as Annexure-1. 2. Resignation of Ms. Manali Patel as Non-Executive, Independent Director of the Company 3. Appointment of Ms. Apeksha Vyas as Additional Non-executive Independent Director of the Company 4. Resignation of Mr. Girish Bhatt as Managing Director of the Company 5. Appointment of Mr. Jayendra Mehta as Managing Director of the Company (As Per BSE Announcement dated on 25.04.2023) With refrence to the Outcome filed on 25th April, 2023 and with reference to the email received from BSE dated 22nd September, 2023, we are enclosing the revised outcome for the discrpancy. (As Per BSE Announcement dated on 28.09.2023)
22-Mar-2023	29-Mar-2023	Others	Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/03/2023 inter alia to consider and approve 1. To review the performance of non-independent directors and the Board as a Whole; 2. To review the performance of the Chairperson of the company taking into account the views of executive directors and non-executive directors; 3. To assess the quality quantity and timeliness of flow of information between the company management and the Board that is necessary for the Board to effectively and reasonably perform their duties; 4. Any other business with the permission of chair. We wish to inform you that pursuant to Regulation 25(3) and other applicable regulation of SEBI (LODR) and Schedule IV of the Companies Act, 2013 and other applicable provisions of the Companies Act, 2013, a separate meeting of Independent Director is held on today i.e., March 29, 2023 and transacted the following businesses: 1. Reviewed the performance of non-independent directors and the board of directors as whole of the Company. 2. Reviewed the performance of the Chairperson of the company taking into account the views of Executive Directors and Non-Executive Directors. 3. Assessed the quality, quantity and timelines of flow of information between the Management of the Company and the Board of directors to effectively and reasonably perform their duties. (As per BSE Announcement Dated on 29/03/2023)
25-Feb-2023	04-Mar-2023	Stock Split	Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/03/2023 inter alia to consider and approve the Record Date for the purpose of determining eligibility of shareholders for the purpose of sub-division of one (1) Equity Share having face value of Rs.10/- (Rupees Ten) each into 10 (Ten) Equity Shares of nominal value of Rs. 1/- each in the Share Capital of the Company as approved by the Shareholder in the Extra-Ordinary General Meeting of the Company held on Friday February 24 2023 and any other business with the permission of Chair. Board of Directors of the Company at its meeting held today i.e. Saturday, March 04, 2023 at Registered Office of the Company has inter alia considered and approved the Friday, March 24, 2023 Record Date for the purpose of determining eligibility of shareholders for the purpose of subdivision of one (1) Equity Share having face value of Rs.10/- (Rupees Ten) each into 10 (Ten) Equity Shares of nominal value of Rs. 1/- each in the Share Capital of the Company. (As per BSE Announcement Dated on 04/03/2023)
12-Jan-2023	24-Jan-2023	Quarterly Results	Vivanza Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2023 inter alia to consider and approve 1. Un-audited Standalone and Consolidated Financial Results along with Limited Review Report of the Company for the Quarter and Nine Months ended on December 31st 2022; 2. Proposal for sub-division of the Equity shares of the Company having a face value of Rs. 10/- each in such manner as may be determined by the Board of Directors; 3. Alteration of Authorised Share Capital clause of the Company; 4. Approve the draft notice of Extra-Ordinary General Meeting (EOGM); 5. Fix the Book Closure date for the purpose of Extra- Ordinary General Meeting (EOGM); 6. Appoint scrutinizer to ascertain voting process of Extra- Ordinary General Meeting (EOGM); 7. Any other business with the permission of chair; Board the Board considered the proposal for sub-division of 1 (One) equity share of the Company having face value of Rs. 10/- each into 10 (Ten) equity shares having face value of Rs. 1/- each, subject to regulatory/statutory approvals as may be required and the approval of the members of the Company. Further, the Board recommended consequential amendments in the Capital Clause of the Memorandum of Association of the Company, subject to approval of the members of the Company. (As Per BSE Bulletin Dated on 24.01.2023) CONSIDERED AND APPROVED: 1.STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED DECEMBER, 2022 2.SUB-DIVISION OF EQUITY SHARES (As Per BSE Announcement Dated on 24/01/2023)

1 2 3

LOGIN HERE

Vivanza Biosciences Ltd

Board Meeting